Human inter-alpha-trypsin inhibitor. Limited proteolysis by trypsin, plasmin, kallikrein and granulocytic elastase and inhibitory properties of the cleavage products.
The acid-labile inter-alpha-trypsin inhibitor is cleaved enzymatically in vivo, liberating a smaller acid-stable inhibitor. The molar ratio of native inhibitor to this smaller inhibitor in plasma is significantly changed in some severe cases of inflammation and kidney injury. To clarify this observation on a molecular basis, the action of four different types of proteinases (trypsin, plasmin, kallikrein and granulocyte elastase) on the inter-alpha-trypsin inhibitor was studied. The initial rate of cleavage of the inter-alpha-trypsin inhibitor by a 1.3-fold molar excess of proteinase over inhibitor was found to be 4375 nM x min-1 with granulocyte elastase, 860 nM x min-1 with trypsin, 67 nM x min-1 with plasmin, and 0.3 nM X min-1 with kallikrein. Obviously, of the enzymes studied so far, the granulocyte elastase known to be released during severe inflammatory processes is by far the most potent proteinase in the transformation of the inter-alpha-trypsin inhibitor. The inter-alpha-trypsin inhibitor and its cleavage products inhibit bovine trypsin very strongly (Ki = 10(-9)--10(-11) M), porcine plasmin much less strongly, human plasmin very weakly and pancreatic kallikrein practically not at all.
D000510:Alpha-Globulins / Q000494:pharmacology; D000818:Animals; D005341:Fibrinolysin / Q000378:metabolism*; D006098:Granulocytes / Q000201:enzymology; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D007700:Kinetics; D010196:Pancreatic Elastase / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D013552:Swine; D014357:Trypsin / Q000378:metabolism*; D014361:Trypsin Inhibitors / Q000494:pharmacology
D000510:Alpha-Globulins; D010446:Peptide Fragments; D014361:Trypsin Inhibitors; C011877:inter-alpha-inhibitor; D007610:Kallikreins; D010196:Pancreatic Elastase; D014357:Trypsin; D005341:Fibrinolysin